A
Accriva Diagnostics
Health Tech & Medtech · San Diego, United States · Founded 2010
Near patient testing systems and advanced diagnostic solutions MoreLess
Accriva Diagnostics is a pioneering company in the field of in vitro diagnostics, specializing in Hemostasis and Acute Care Diagnostics. Since its inception in 1959, the company has been at the forefront of innovation, consistently delivering high-quality diagnostic systems, reagents, data management solutions, and comprehensive services. Accriva serves a diverse range of clients, including hospitals, laboratories, and intensive care units, ensuring optimal patient care through its advanced diagnostic solutions.
Operating in a global market, Accriva has a significant presence across America, Asia Pacific, Europe, the Middle East, and Africa. The company's business model revolves around the development, manufacturing, and distribution of diagnostic systems and reagents, which are essential for accurate and timely medical diagnostics. Revenue is generated through the sale of these products and the provision of related services, including system optimization, training, and customer support.
Accriva's commitment to quality and innovation is evident in its award-winning products and continuous upward sales trajectory. The company's integrative solutions are designed to support the continuum of hospital care, ensuring that healthcare providers have the tools they need to deliver the highest level of patient care.
Keywords: Hemostasis, Acute Care Diagnostics, in vitro diagnostics, diagnostic systems, reagents, data management, patient care, hospitals, laboratories, global market.
Company overview
Accriva Diagnostics company information
The essential company record, classifications and operating signals in one place.
- Status
- Acquired
- Founded
- 2010
- Headquarters
- San Diego, United States
- Employees
- 87
- Open positions
- None listed
- Dealroom signal
- 34.8
Valuation & funding
Accriva Diagnostics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Jan 2017 | $0 | — | Werfen | ↗ |
| LATE VC✓Equity / VC | Mar 2015 | $16M | $62M | Warburg Pincus | — |
| MERGER✓Other financing | Sep 2013 | $0 | — | Accumetrics · ITC | ↗ |
| SERIES A✓Equity / VC | Nov 2010 | $0 | — | Bay City Capital | — |
Financials
Revenue and workforce over time
Available revenue and workforce history. Fields without reported data are omitted.
| Year | Revenue | Growth | Employees |
|---|---|---|---|
| 2026 | $94M | 0% | 87 |
| 2025 | $94M | 0% | 115 |
| 2024 | $94M | 0% | 115 |
| 2023 | $94M | 0% | 115 |
| 2022 | $94M | 0% | 115 |
| 2021 | $94M | 0% | 115 |
| 2020 | $94M | — | 134 |
Growth signals
Accriva Diagnostics website traffic
Latest recorded traffic for Accriva Diagnostics is 150 monthly website visits, down 11.8% over the last three months. Accriva Diagnostics's team declined 24.3% over the past year.
Comparisons
Accriva Diagnostics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Accriva Diagnostics's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Accriva Diagnostics has talent and traffic
team presence
In the news
Latest news about Accriva Diagnostics
Recent press, funding announcements, and product moves mentioning Accriva Diagnostics — open to read from the original sources.
Market sentiment
What the market is saying about Accriva Diagnostics
An AI-synthesized read of the highest-engagement posts about Accriva Diagnostics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Accriva Diagnostics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.